# A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

> **NCT06497985** · PHASE3 · RECRUITING · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 430 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Tucidinostat
- **DRUG:** Sintilimab
- **DRUG:** Bevacizumab
- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT06497985
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-06
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06497985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06497985, "A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06497985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*